TOP2A
DNA topoisomerase 2-alpha
As of the edition of 20 October 2026, TOP2A (DNA topoisomerase 2-alpha, UniProt P11388) has 20 drugs tested at it and 37 companies on the list, 10 on route A and 10 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11388
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 15
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Hormones
- Registered trials of its drugs
- 3,566
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 12 |
| Active | 2 |
| Stopped | 6 |
| Total | 20 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Doxorubicin | Marketed | Phase 4 | none listed |
| Etoposide | Marketed | Phase 4 | none listed |
| Epirubicin | Marketed | Phase 4 | none listed |
| Mitoxantrone | Marketed | Phase 4 | none listed |
| Daunorubicin | Marketed | Phase 4 | none listed |
| Idarubicin | Marketed | Phase 4 | none listed |
| Etoposide phosphate | Marketed | Phase 4 | none listed |
| Dexrazoxane | Marketed | Phase 3 | none listed |
| Aldoxorubicin | Stopped | Phase 3 | none listed |
| Amrubicin | Active | Phase 3 | none listed |
| Teniposide | Marketed | Phase 4 | none listed |
| Aclarubicin | Active | Phase 3 | none listed |
12 of 20 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 10 |
| Route B | 10 |
| Engaged | 13 |
| Undetermined | 4 |
| Total on the list | 37 |
| Company | Route |
|---|---|
| Immunitybio | Route A |
| Hq Specialty Pharma | Route B |
| CNX Therapeutics | Route B |
The other 34 companies at TOP2A
In the product37 companies in all; 34 are not named here, and no score is.
See the 37 companies at TOP2A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.